You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,232,572


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,232,572
Title:Methods of treating rosacea
Abstract:A method of treating rosacea in a human in need thereof comprising administering to said human a tetracycline compound in an amount that is effective to treat rosacea, but has substantially no antibiotic activity.
Inventor(s): Ashley; Robert A. (Tucson, AZ)
Assignee: CollaGenex Pharmaceuticals, Inc. (Newtown, PA)
Application Number:11/061,866
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,232,572
Patent Claims: 1. A method for treating papules and pustules of rosacea in a human in need thereof comprising administering orally to said human a tetracycline compound, or a pharmaceutically acceptable salt thereof, in an amount that is effective to treat the papules and pustules of rosacea, but has substantially no antibiotic activity, said amount being 10-80% of the antibiotic amount, wherein the tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount that results in no reduction of skin microflora during a six-month treatment, without administering a bisphosphonate compound.

2. A method according to claim 1, wherein said tetracycline compound is minocycline or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration of 0.8 .mu.g/ml.

3. A method according to claim 1, wherein said tetracycline compound is tetracycline or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration of 0.5 .mu.g/ml.

4. A method according to claim 1, wherein said tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration which is 10-80% of the minimum antibiotic serum concentration.

5. A method according to claim 4, wherein said antibiotic tetracycline compound is doxycycline, minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts of any such compound.

6. A method according to claim 5, wherein said antibiotic tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof.

7. A method according to claim 6, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount which provides a serum concentration in the range of about 0.1 to about 0.8 .mu.g/ml.

8. A method according to claim 6, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 20 milligrams twice daily.

9. A method according to claim 7, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered by sustained release.

10. A method according to claim 9, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 40 milligrams.

11. A method according to claim 1, wherein said tetracycline compound is an antibiotic tetracycline compound or a pharmaceutically acceptable salt thereof administered in an amount which is 10-70% of the antibiotic amount.

12. A method according to claim 1, wherein said tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof.

13. A method according to claim 12, wherein said doxycycline is doxycycline monohydrate.

14. A method according to claim 12, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered in an amount of 40 milligrams.

15. A method according to claim 14, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered by sustained release.

16. A method according to claim 12, wherein said doxycycline or pharmaceutically acceptable salt thereof is administered twice a day in a dose of 20 mg.

17. A method according to claim 1, wherein said tetracycline compound is minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts of any such compound.

18. A method according to claim 4, wherein said tetracycline compound is doxycycline or a pharmaceutically acceptable salt thereof administered in an amount which results in a serum concentration of approximately 1.0 .mu.g/ml.

19. A method according to claim 4, wherein said tetracycline compound is minocycline, tetracycline, oxytetracycline, chlortetracycline, demeclocycline or pharmaceutically acceptable salts of any such compound.

20. A method for treating papules and pustules of rosacea in a human in need thereof comprising administering orally to said human a hydrate of doxycycline in an amount that is effective to treat the papules and pustules of rosacea, but has substantially no antibiotic activity, said amount being 10-80% of the antibiotic amount, wherein the hydrate of doxycycline is administered in an amount that results in no reduction of skin microflora during a six-month treatment, said method not comprising administering a bisphosphonate compound.

21. A method according to claim 20, wherein said hydrate of doxycycline is doxycycline monohydrate.

22. A method according to claim 20 wherein said hydrate of doxycycline is administered in an amount which is 10-70% of the antibiotic amount.

23. A method according to claim 20, wherein said hydrate of doxycycline is administered in an amount of 40 milligrams.

24. A method according to claim 20, wherein said hydrate of doxycycline is administered by sustained release.

25. A method according to claim 20, wherein said hydrate of doxycycline is administered twice a day in a dose of 20 mg.

26. A method according to claim 23, wherein said hydrate of doxycycline is administered once a day.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.